CRISPR Therapeutics AG (CRSP) Receivables (2015 - 2024)
CRISPR Therapeutics AG (CRSP) posted Receivables of $27.1 million for Q4 2024, down 86.88% sequentially from $206.5 million in Q4 2023, and down 86.88% YoY from $206.5 million in Q1 2024.
CRISPR Therapeutics AG (CRSP) Receivables (2015 - 2024) Analysis & Trends
CRISPR Therapeutics AG has reported Receivables for 10 years, with the latest figure at $27.1 million in Q4 2024.
- Quarterly Receivables fell 86.88% year-over-year to $27.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $27.1 million (down 86.88% YoY) and the FY2024 annual result came in at $27.1 million, down 86.88% from the prior year.
- Receivables retreated to $27.1 million in Q4 2024 per CRSP's latest filing, from $206.5 million in the prior quarter.
- Over five years, Receivables peaked at $206.5 million in Q4 2023 and troughed at $49000.0 in Q3 2022.
- A 5-year average of $29.0 million and a median of $10.8 million in 2020 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2023: Receivables slumped 99.7% in 2021, then soared 105960.61% in 2023.
- Over 5 years, Receivables stood at $10.8 million in 2020, then dropped by 19.73% to $8.7 million in 2021, then grew by 28.66% to $11.2 million in 2022, then soared by 1743.75% to $206.5 million in 2023, then tumbled by 86.88% to $27.1 million in 2024.
- According to Business Quant data, Receivables over the past three periods registered $27.1 million, $206.5 million, and $70.0 million for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 27.10 Mn |
| Dec 31, 2023 | 206.50 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Dec 31, 2022 | 11.20 Mn |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 66,000.00 |
| Mar 31, 2022 | 143,000.00 |
| Dec 31, 2021 | 8.71 Mn |
| Sep 30, 2021 | 152,000.00 |
| Jun 30, 2021 | 150,000.00 |
| Mar 31, 2021 | 150,000.00 |
| Dec 31, 2020 | 10.84 Mn |
| Sep 30, 2020 | 25.11 Mn |
| Jun 30, 2020 | 25.03 Mn |
| Mar 31, 2020 | 50.12 Mn |
| Dec 31, 2019 | 29.80 Mn |
| Sep 30, 2019 | 27.20 Mn |
| Jun 30, 2019 | 3.12 Mn |
| Mar 31, 2019 | 4.33 Mn |
| Dec 31, 2018 | 176,000.00 |